Key result
Osimertinib successfully improved dysphagia caused by paraneoplastic neurological syndrome in a patient with EGFR mutation-positive lung adenocarcinoma within seven days, with no recurrence for 10 months.
Why the study?
Lung cancer is the most common underlying cause of paraneoplastic neurological syndrome, but reports in non-small cell lung cancer are rare.
Does osimertinib improve dysphagia due to paraneoplastic neurological syndrome in a patient with EGFR mutation-positive lung adenocarcinoma?
Case Report (n=1)
No
Does osimertinib improve dysphagia due to paraneoplastic neurological syndrome in a patient with EGFR mutation-positive lung adenocarcinoma?
Molecular-targeted therapy with osimertinib can improve paraneoplastic neurological syndrome in patients with EGFR mutation-positive lung adenocarcinoma.
Osimertinib was associated with paraneoplastic dysphagia resolution in EGFR-mutant lung adenocarcinoma; leaves open whether targeted therapy improves such syndromes more broadly.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hiruta et al. (2023) conducted a case report in Paraneoplastic Neurological Syndrome arising from Lung Cancer (n=1). Osimertinib was evaluated on Improvement of dysphagia. Osimertinib successfully improved dysphagia caused by paraneoplastic neurological syndrome in a patient with EGFR mutation-positive lung adenocarcinoma within seven days, with no recurrence for 10 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: